Qual é o horário de funcionamento?

Segunda-feira 09:00 - 17:30 Terça-feira 09:00 - 17:30 Quarta-feira 09:00 - 17:30 Quinta-feira 09:00 - 17:30 Sexta-feira 09:00 - 17:30

Clevidence

Name: Clevidence
Address: Avenida Jacques Delors, Edifício Inovação II, 411/421, Porto Salvo, 2740-122, PT
Telephone: +351913852490

Ligar Como chegar Website Contactar o negócio

Clevidence stands for clear evidence.

Our aim is to deliver evidence-based assessments that can be used with confidence by health decision-makers and other stakeholders in healthcare.

21/10/2026

A stronger HTA submission often begins before the dossier does. Before drafting, three questions can reveal where the greatest risks may lie.

Early clarity creates room to address evidence gaps, align analyses and strengthen the rationale behind methodological choices.
Need support? Talk to Clevidence.

16/10/2026

Clevidence is heading to ISPOR Europe 2026.

From 8 to 11 November, the global HEOR community will gather in Vienna to explore how science, evidence and policy can help shape the future of healthcare access.

Our team will be there to exchange perspectives, discuss the evolving evidence and market access landscape, and connect with professionals working to support better-informed healthcare decisions.

Planning to attend?

Register for ISPOR Europe 2026 and add Stand 428 to your event plan. Come and meet the Clevidence team in Vienna.

📍 Austria Center Vienna, Vienna, Austria
📅 8 to 11 November 2026
📌 Stand 428

🔗 You can register here: https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-europe-2026

14/10/2026

PICO is often presented as a framework for structuring a research question.

In HTA, it can do much more. Population, intervention, comparator and outcomes influence which evidence is relevant, which analyses are feasible and where uncertainty may emerge.

When anticipated early, PICO scenarios can help teams prepare an evidence strategy that is more coherent, traceable and responsive to HTA requirements.
The earlier the question is understood, the better the evidence can be prepared to answer it.

We support teams in translating anticipated HTA questions into evidence strategies.
Develop yours with Clevidence.

07/10/2026

The publication of the JCA report is not the end of the access journey. It marks the transition into the national phase.

For market access teams, this means that European-level assessment and national preparation should not be treated as separate, sequential steps. While the JCA progresses, there is already work that can be advanced at country level, from economic modelling and national dossier development to pricing and reimbursement strategy.

In Portugal, this coordination is particularly important as the new national framework incorporates the JCA report into the INFARMED assessment process.

At Clevidence, we support this transition from JCA to national market access with an integrated evidence and reimbursement strategy. Get in touch.

30/09/2026

A reliable systematic review depends on much more than identifying relevant studies.

It starts with a clear research question, follows predefined methods and uses a structured, transparent search process to identify the relevant evidence.

Just as importantly, the included studies must be critically assessed. Understanding their risk of bias and consistency of the evidence helps determine how much confidence can be placed in the findings.

The reliability of a systematic review ultimately depends on how rigorously the evidence is identified, assessed and interpreted.

23/09/2026

QALYs are widely used in economic evaluation because they bring length of life and health-related quality of life into a single measure.

But their value lies not only in the number itself. QALYs can help decision-makers compare the health benefits generated by different interventions and consider those gains alongside the resources required to achieve them.

At the same time, no single measure can capture every aspect of value. Clinical context, uncertainty, equity and patient needs may all influence how evidence should be interpreted.

So, even though QALYs are useful, they are only one part of understanding the overall value of a health technology.

16/09/2026

Clinical outcomes are essential for understanding whether an intervention produces measurable changes in health. But they do not always tell us how those changes are experienced by patients.

Symptoms, daily functioning, emotional well-being and quality of life reported by patients can reveal dimensions of treatment benefit that traditional clinical endpoints may not fully capture.

Bringing clinical and patient-reported outcomes perspectives together can provide a more complete understanding of an intervention’s impact, particularly when generating evidence to support healthcare decision-making.

09/09/2026

A robust economic evaluation is not simply a matter of choosing an established analytical approach. It requires understanding how a technology creates value, where uncertainty lies, and which outcomes matter most to the decision at hand.

That distinction is increasingly important as healthcare technologies become more diverse. The assumptions that work well for one intervention may be inappropriate for another, particularly when technologies differ in their implementation, evidence base, time horizon or impact on clinical practice.

Methodological rigour therefore depends not only on applying the right techniques, but on applying them in the right context.

27/08/2026

A dossier is not judged only by the evidence it contains, but by how clearly its reasoning can be followed.

In complex HTA work, some limitations are unavoidable. What matters is whether they are identified early, documented consistently and linked to the decisions made throughout the analysis.

That is why the first working version should be treated as more than a draft. It is the point at which the analytical logic becomes visible, assumptions can be challenged and potential weaknesses can be addressed before they become harder to resolve.

A defensible dossier does not hide uncertainty. It explains it.

At Clevidence, we support teams in developing clear, traceable and scientifically robust dossiers for HTA and JCA processes.

Get in touch to discuss and strengthen your dossier strategy.

24/08/2026

Comparator strategy is not simply a technical choice. It sits at the intersection of clinical relevance, HTA requirements and national reimbursement practice.

A comparator may appear scientifically reasonable but still fail to reflect the decision context in which the evidence will be assessed. That misalignment can affect the interpretation of relative effectiveness, the feasibility of indirect comparisons and, ultimately, the strength of the value case.

The earlier comparator assumptions are tested across priority markets, the more opportunity there is to refine the evidence plan and reduce avoidable risk.

At Clevidence, we help teams assess comparator relevance from an HTA, pricing and reimbursement perspective.

Get in touch to review your comparator strategy.

Endereço

Avenida Jacques Delors, Edifício Inovação II, 411/421
Porto Salvo
2740-122

Horário de Funcionamento

Segunda-feira	09:00 - 17:30
Terça-feira	09:00 - 17:30
Quarta-feira	09:00 - 17:30
Quinta-feira	09:00 - 17:30
Sexta-feira	09:00 - 17:30

Telefone

+351913852490

Website

http://clevidence.pt/

Notificações

Seja o primeiro a saber: enviamos-lhe um e-mail quando Clevidence publicar novidades e promoções. O seu endereço de e-mail não será utilizado para nenhum outro fim e pode cancelar a subscrição a qualquer momento.